Brii Biosciences Reports 42.9% HBsAg Loss With BRII-179 Combination in HBV Study
Brii Biosciences reports 42.9% HBsAg loss with BRII-179 combination in HBV study, significantly exceeding standard-of-care monotherapy results.
Akeso’s AK157D1 B7-H3 ADC Cleared for Phase I Trial in Solid Tumors
Akeso's AK157D1 B7-H3 ADC wins Phase I clearance in China for advanced solid tumors, targeting a protein overexpressed in...
FDA Clears PrecivityAD2 Blood Test for Alzheimer’s in Adults as Young as 40
FDA clears PrecivityAD2 blood test for Alzheimer's in adults as young as 40, expanding early detection and clinical trial...
iPSC Cardiomyocytes Reach the Beating Heart: What This Trial Design Tells Sponsors About the Next Frontier of Cell Therapy Protocols
A Nature Medicine RCT of allogeneic iPSC-derived cardiomyocytes in advanced ischemic heart failure just set the protocol bar for...
When Your CRO Gets Acquired, Your Site Activation Timeline Pays the Price
Curavit's acquisition of Lindus Health CRO assets combines 1,000+ global sites with DCT infrastructure—but site teams absorb the operational...
When Your CRO Gets Acquired Mid-Study, Your Site Feels It First
Curavit's acquisition of Lindus Health's CRO assets unifies 13,478 sites across 79 countries — but site teams will navigate...
Upadacitinib’s Phase 3 Vitiligo Data Just Redrew the Regulatory Map for JAK Inhibitors in Dermatology
AbbVie's Viti-Up trials showed upadacitinib 15mg hit F-VASI 75 in vitiligo across two Phase 3 studies—here's what the trial...
Curavit Acquires Lindus Health CRO Assets to Expand U.S.-European Operations
Curavit acquires Lindus Health CRO assets to unify U.S.-European clinical trial operations and accelerate site activation across decentralized studies.
CARsgen’s satricabtagene autoleucel approved for gastric cancer in China
Satricabtagene autoleucel becomes the first CAR-T cell therapy approved for solid tumors, achieving a 22% response rate in advanced...
Amylyx’s avexitide meets Phase 3 endpoints in post-bariatric hypoglycemia trial
Amylyx's avexitide meets Phase 3 endpoints in post-bariatric hypoglycemia trial, offering the first FDA-backed treatment option for a condition...